Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

por le Roux, Carel W., Zhang, Shuyu, Aronne, Louis J., Kushner, Robert F., Chao, Ariana M., Machineni, Sriram, Dunn, Julia, Chigutsa, Farai B., Ahmad, Nadia N., Bunck, Mathijs C.
Publicado 2022

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

por Wadden, Thomas A., Chao, Ariana M., Machineni, Sriram, Kushner, Robert, Ard, Jamy, Srivastava, Gitanjali, Halpern, Bruno, Zhang, Shuyu, Chen, Jiaxun, Bunck, Mathijs C., Ahmad, Nadia N., Forrester, Tammy
Publicado 2023

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

por Perreault, Leigh, Davies, Melanie, Frias, Juan P., Laursen, Peter Nørkjaer, Lingvay, Ildiko, Machineni, Sriram, Varbo, Anette, Wilding, John P.H., Wallenstein, Signe Olrik Rytter, le Roux, Carel W.
Publicado 2022